New Chen, Chairman of Big Vision, was appointed as an expert in the National Expert Group for Artificial Intelligence Medical Device Standardization Technical Focal Point

In recent years, artificial intelligence has shown excellent technical strength and development prospects in the field of healthcare, and a large number of products have entered the market transformation stage both at home and abroad. In order to meet the development needs of the medical device industry, in March 2019, the State Drug Administration issued the “Artificial Intelligence Medical Device Standardization Technical Focal Point Unit Formation Program”. Artificial intelligence medical device standardization technology focal point unit is mainly responsible for the terminology and classification, data set quality management, basic common technology, quality management system, product evaluation process, special methods involved in artificial intelligence medical devices and other industry medical device standards development and revision work, Big Vision as a member of the group. Recently, Mr. Chen Xinjian, Chairman of Big Vision, received an appointment letter and was formally appointed as the expert of the first group of standardized technical focal points for artificial intelligence medical devices.

Since its establishment, Big Vision has focused on the development and manufacturing of artificial intelligence analysis and diagnosis systems for ophthalmic diseases, and is committed to becoming the world’s top ophthalmic imaging diagnostic company. The company has taken the lead in developing and completing the OCT multimodal ophthalmic image assisted diagnosis system, which has been applied in many top ophthalmic hospitals in China. At the National Fundus Forum in Shanghai in November 2019, the BV1000, a fully automatic artificial intelligence OCT developed by the company with fully independent intellectual property rights, became the hot spot of the whole audience when it was first unveiled, with long queues of users coming to experience it, and everyone spoke highly of the interactive friendliness and artificial intelligence functions of the BV 1000 operation.

The appointment of Chen Xinjian, the chairman of the company, is another affirmation and recognition of Big Vision’s continuous efforts and technical strength in the field of ophthalmic imaging artificial intelligence. Looking ahead, Big Vision will continue to uphold the corporate spirit of “dream, passion, and practicality” and forge ahead to empower ophthalmology treatment with artificial intelligence and create more value for users.